Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort

Carcinogenesis. 2016 Mar;37(3):262-8. doi: 10.1093/carcin/bgw001. Epub 2016 Jan 16.


Prostate cancer patients with inherited BRCA2 mutations have a survival disadvantage. However, it is unknown whether progression is associated with BRCA2 protein expression in diagnostic prostate cancer tissue, among men without inherited mutations. We conducted a nested case-control study within the Swedish Watchful Waiting cohort. The case group included all 71 patients who died from prostate cancer within 5 years from diagnosis and controls were all patients (n = 165) who lived at least 7 years after diagnosis. Tissue microarrays were stained using antibodies for C- and N-terminal domains of the BRCA2 protein. Location (nuclear, cytoplasmic and membranous) and magnitude (intensity and percentage) of expression were assessed. Logistic regression models produced odds ratios (OR) and 95% confidence intervals (CI) adjusted for age, year of diagnosis and Gleason score. Positive BRCA2 staining at the cell membrane was associated with reduced risk of death within 5 years (N-terminal: OR = 0.47, 95% CI = 0.21-1.04, P = 0.06; C-terminal: OR = 0.41, 95% CI = 0.18-0.91, P = 0.03) and low Gleason scores (P = 0.006). Positive cytoplasmic C-terminal staining was associated with higher Gleason scores and increased lethality (OR = 3.61, 95% CI = 1.61-8.07, P = 0.002). BRCA2 protein expression at the cell membrane and lack of C-terminal expression in the cytoplasm were associated with a reduced risk of rapidly fatal prostate cancer. BRCA2 protein expression in prostate cancer tissue may have independent prognostic value. The potential biological significance of BRCA2 expression at the cell membrane warrants further investigation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • BRCA2 Protein / analysis
  • BRCA2 Protein / metabolism*
  • Biomarkers, Tumor / analysis*
  • Case-Control Studies
  • Cell Membrane / metabolism
  • Cell Nucleus / metabolism
  • Cohort Studies
  • Cytoplasm / metabolism
  • Disease Progression
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Prognosis
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Tissue Array Analysis
  • Watchful Waiting


  • BRCA2 Protein
  • BRCA2 protein, human
  • Biomarkers, Tumor